Kinase Domain Mutations in Cancer: Implications for Small Molecule Drug Design Strategies

This publication has 104 references indexed in Scilit:

• Activation of tyrosine kinases by mutation of the gatekeeper threonine
  Nature Structural & Molecular Biology, 2008
• Discovery of Drug-Resistant and Drug-Sensitizing Mutations in the Oncogenic PI3K Isoform p110α
  Cancer Cell, 2008
• BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
  Oncogene, 2008
• Inhibition of the EGF receptor by binding of MIG6 to an activating kinase domain interface
  Nature, 2007
• Structures of Lung Cancer-Derived EGFR Mutants and Inhibitor Complexes: Mechanism of Activation and Insights into Differential Inhibitor Sensitivity
  Cancer Cell, 2007
• An Allosteric Mechanism for Activation of the Kinase Domain of Epidermal Growth Factor Receptor
  Cell, 2006
• ERBB receptors and cancer: the complexity of targeted inhibitors
  Nature Reviews Cancer, 2005
• Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial
  The Lancet, 2004
• Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors
  New England Journal of Medicine, 2002
• Mutations of the BRAF gene in human cancer
  Nature, 2002